Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients

NCT ID: NCT00787293

Last Updated: 2011-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implantable device.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Mitral Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.

Group Type EXPERIMENTAL

PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant

Intervention Type DEVICE

Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant

Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Functional MR 2+ - 4+
* Symptomatic heart failure, NYHA Class II to IV
* LVEF \> 25% or \< 50% OR dilated mitral annulus \> 30mm

Exclusion Criteria

* MR of organic origin
* Severe mitral leaflet tethering
* History of MI or PCI within 60 days of study procedure
* Inability to walk a minimum of 100 meters in 6 minutes
* Significant left main stenosis or proximal circumflex stent
* Indication of non-patent CSO or discontinuous CS-GCV-AIV
* Bi-ventricular with leads in CS or other devices impeding device placement
* Severe aortic valvular disease
* Chronic corticosteroid use other than \< 20mg prednisone for arthritis
* Significant co-morbidities
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Duke University

OTHER

Sponsor Role collaborator

Medifacts International Corporation

INDUSTRY

Sponsor Role collaborator

Viacor

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Viacor, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefan Sack, Md, PhD

Role: PRINCIPAL_INVESTIGATOR

Klinikum Schwabing, Staedtisches Klinikum Muenchen GmbH

Rainer Hoffmann, MD

Role: PRINCIPAL_INVESTIGATOR

R-WTH Universitätsklinikum Aachen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Onze Lieve Vrouw Ziekenhuis Cardiovasculair Ondrezoek Aalst

Aalst, , Belgium

Site Status

Centre Hospitalier Universitaire de Liège

Liège, , Belgium

Site Status

Institut Klinicke a Experimentalni Mediciny

Prague, , Czechia

Site Status

Rheinisch-Westfalische Technische Hochschule Universitaetsklinikum Aachen

Aachen, , Germany

Site Status

Herz-und Diabeteszentrum Nordrhein-Westfalen / Ruhr University of Bochum

Bad Oeynhausen, , Germany

Site Status

Universitaet Duisburg-Essen Westdeutsches Herzzentrum Universitaetsklinikum Essen

Essen, , Germany

Site Status

CardioVascular Center Frankfurt Sankt Katharinen

Frankfurt, , Germany

Site Status

Albert-Ludwigs-Universitat Freiburg Mediziniche Universitätsklinikum Freiburg

Freiburg im Breisgau, , Germany

Site Status

Städtische Klinikum Karlsruhe GmbH

Karlsruhe, , Germany

Site Status

Klinikum Schwabing Städtisches Klinikum München GmbH

München, , Germany

Site Status

Thoraxcentrum Erasmus Medisch Centrum

Rotterdam, , Netherlands

Site Status

Universitair Medisch Centrum Utrecht

Utrecht, , Netherlands

Site Status

Hôpital Universitaire de Genève

Geneva, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Czechia Germany Netherlands Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Fukuda S, Gillinov AM, Liddicoat JR, Saracino G, Hayase M, Cohn WE, Schneider CW, Shiota T. Maintenance of geometric alterations associated with percutaneous mitral valve repair: real-time three-dimensional echocardiographic assessment in an ovine model. J Heart Valve Dis. 2008 May;17(3):276-82.

Reference Type BACKGROUND
PMID: 18592924 (View on PubMed)

Daimon M, Gillinov AM, Liddicoat JR, Saracino G, Fukuda S, Koyama Y, Hayase M, Cohn WE, Ellis SG, Thomas JD, Shiota T. Dynamic change in mitral annular area and motion during percutaneous mitral annuloplasty for ischemic mitral regurgitation: preliminary animal study with real-time 3-dimensional echocardiography. J Am Soc Echocardiogr. 2007 Apr;20(4):381-8. doi: 10.1016/j.echo.2006.08.029.

Reference Type BACKGROUND
PMID: 17400117 (View on PubMed)

Dubreuil O, Basmadjian A, Ducharme A, Thibault B, Crepeau J, Lam JY, Bilodeau L. Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: first in man experience with a temporary implant. Catheter Cardiovasc Interv. 2007 Jun 1;69(7):1053-61. doi: 10.1002/ccd.21186.

Reference Type BACKGROUND
PMID: 17525965 (View on PubMed)

Daimon M, Shiota T, Gillinov AM, Hayase M, Ruel M, Cohn WE, Blacker SJ, Liddicoat JR. Percutaneous mitral valve repair for chronic ischemic mitral regurgitation: a real-time three-dimensional echocardiographic study in an ovine model. Circulation. 2005 May 3;111(17):2183-9. doi: 10.1161/01.CIR.0000163547.03188.AC. Epub 2005 Apr 25.

Reference Type BACKGROUND
PMID: 15851597 (View on PubMed)

Liddicoat JR, Mac Neill BD, Gillinov AM, Cohn WE, Chin CH, Prado AD, Pandian NG, Oesterle SN. Percutaneous mitral valve repair: a feasibility study in an ovine model of acute ischemic mitral regurgitation. Catheter Cardiovasc Interv. 2003 Nov;60(3):410-6. doi: 10.1002/ccd.10662.

Reference Type BACKGROUND
PMID: 14571496 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08-010P

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.